Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$15.69 USD
-0.06 (-0.38%)
Updated May 3, 2024 04:00 PM ET
After-Market: $15.68 -0.01 (-0.06%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 21 - 40 ( 189 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine New Drug Application Submitted on Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
NDA Submitted for Ensifentrine/COPD; On-Track for Potential Approval in H1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Pivotal Trial Expanded Analyses Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE-ing Our Understanding of Ensifentrine with ATS Posters Mgmt Dinner
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ATS Presentations to Showcase Additional Ph3 ENHANCE Program Analyses; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Regulatory Submission Preparations Ongoing; 1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Phase 3 Trial in China Doses First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Advantage Ensifentrine; Competitor Data Underscores Ensi''s Broad Potential
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
New Drug Application Timing Unchanged; 2022 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY22 Financials; Ensifentrine/COPD NDA Submission in Q2:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A